- Reaction score
- 136
If
Very nice. I had somehow remained ignorant to this information until now. Thanks.
Ignore the other misinformation on this thread.
It's actually well known why RU did not make it to market, and it's been previously posted on this site. The company simply estimated that RU would not be that profitable, and thus it did not other with phase III clinical trials, marketing, etc.
It's not that hard to see why. This is a small market, and RU was measured to be comparably effective to existing treatments, rather than more effective. If it had been better, they would have released it.
Very nice. I had somehow remained ignorant to this information until now. Thanks.